168 related articles for article (PubMed ID: 35720901)
21. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
[No Abstract] [Full Text] [Related]
22. A systematic approach to decode the mechanism of Cornus in the treatment of hepatocellular carcinoma (HCC).
Shen HY; Li XQ; Fan WQ; Wang YW; Huang F; Wu JQ; Zhang W; Feng XS; Chao X
Eur J Pharmacol; 2021 Oct; 909():174405. PubMed ID: 34384755
[TBL] [Abstract][Full Text] [Related]
23. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
24. Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification.
Wang Y; Chu F; Lin J; Li Y; Johnson N; Zhang J; Gai C; Su Z; Cheng H; Wang L; Ding X
J Ethnopharmacol; 2021 Oct; 279():114399. PubMed ID: 34246740
[TBL] [Abstract][Full Text] [Related]
25. Revealing the potential mechanism of Astragalus membranaceus improving prognosis of hepatocellular carcinoma by combining transcriptomics and network pharmacology.
Liu Z; Ma H; Lai Z
BMC Complement Med Ther; 2021 Oct; 21(1):263. PubMed ID: 34663301
[TBL] [Abstract][Full Text] [Related]
26. Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis.
Mou T; Zhu D; Wei X; Li T; Zheng D; Pu J; Guo Z; Wu Z
World J Surg Oncol; 2017 Mar; 15(1):63. PubMed ID: 28302149
[TBL] [Abstract][Full Text] [Related]
27. Identification of Drug Targets and Agents Associated with Hepatocellular Carcinoma through Integrated Bioinformatics Analysis.
Hossen MA; Reza MS; Harun-Or-Roshid M; Islam MA; Siddika MA; Mollah MNH
Curr Cancer Drug Targets; 2023; 23(7):547-563. PubMed ID: 36786134
[TBL] [Abstract][Full Text] [Related]
28. MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib.
Guo J; Zhao J; Xu Q; Huang D
BMC Cancer; 2023 Oct; 23(1):967. PubMed ID: 37828435
[TBL] [Abstract][Full Text] [Related]
29. [Network pharmacology-based study of the therapeutic mechanism of resveratrol for Alzheimer's disease].
Fang Y; Su Z; Si W; Liu Y; Li J; Zeng P
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Jan; 41(1):10-19. PubMed ID: 33509748
[TBL] [Abstract][Full Text] [Related]
30. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
[TBL] [Abstract][Full Text] [Related]
31. Integration of Network Pharmacology and Molecular Docking Technology Reveals the Mechanism of the Therapeutic Effect of Xixin Decoction on Alzheimer's Disease.
Zhang Z; Xu J; Ma S; Lin N; Hou M; Wei M; Li T; Shi J
Comb Chem High Throughput Screen; 2022; 25(10):1785-1804. PubMed ID: 35616676
[TBL] [Abstract][Full Text] [Related]
32. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
[TBL] [Abstract][Full Text] [Related]
33. Integrated Bioinformatics Analysis for the Screening of Hub Genes and Therapeutic Drugs in Hepatocellular Carcinoma.
Su Q; Li W; Zhang X; Wu R; Zheng K; Zhou T; Dong Y; He Y; Wang D; Ran J
Curr Pharm Biotechnol; 2023; 24(8):1035-1058. PubMed ID: 35762549
[TBL] [Abstract][Full Text] [Related]
34. RARRES1 inhibits hepatocellular carcinoma progression and increases its sensitivity to lenvatinib through interaction with SPINK2.
Guo Y; Chai B; Zhang H; Chai X; Chen Y; Xu J; Qin L; Chai Y
Biol Direct; 2024 Feb; 19(1):15. PubMed ID: 38388961
[TBL] [Abstract][Full Text] [Related]
35. [Bioinformatics analysis of core differentially expressed genes in hepatitis B virus-related hepatocellular carcinoma].
Yu Y; Cheng J; Mei CZ; Dai YZ
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2022 Nov; 34(5):507-513. PubMed ID: 36464255
[TBL] [Abstract][Full Text] [Related]
36. A network pharmacology integrated serum pharmacochemistry strategy for uncovering efficacy of YXC on hepatocellular carcinoma.
Zhou TT; Zhu WJ; Feng H; Ni Y; Li ZW; Sun DD; Li L; Tan JN; Yu CT; Shen WX; Cheng HB
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117125. PubMed ID: 37699493
[TBL] [Abstract][Full Text] [Related]
37. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis.
Shen S; Kong J; Qiu Y; Yang X; Wang W; Yan L
J Cell Biochem; 2019 Jun; 120(6):10069-10081. PubMed ID: 30525236
[TBL] [Abstract][Full Text] [Related]
38. Bioinformatics analysis of key biomarkers and potential molecular mechanisms in hepatocellular carcinoma induced by hepatitis B virus.
Li Z; Xu J; Cui H; Song J; Chen J; Wei J
Medicine (Baltimore); 2020 May; 99(20):e20302. PubMed ID: 32443377
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma.
Xie Y; Yan F; Wang X; Yu L; Yan H; Pu Q; Li W; Yang Z
Cancer Med; 2023 Feb; 12(3):3237-3259. PubMed ID: 36043445
[TBL] [Abstract][Full Text] [Related]
40. Systems Network Pharmacology-Based Prediction and Analysis of Potential Targets and Pharmacological Mechanism of
Hu Y; Yang L; Lu Y; Wang Y; Jiang J; Liu Y; Cao Q
Evid Based Complement Alternat Med; 2022; 2022():2116006. PubMed ID: 36193154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
